Literature DB >> 22661384

Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm.

T Gülen1, B Sander, G Nilsson, J Palmblad, K Sotlar, H-P Horny, H Hägglund.   

Abstract

Systemic mastocytosis (SM) may be associated with a clonal hematopoietic non-mast cell-lineage disease (AHNMD). SM and AHNMD even may be clonally related. This report contributes to a better understanding of the different morphological aspects of SM by demonstrating that various AHNMDs can be detected in one patient during the course of disease. Routinely processed biopsy specimens of bone marrow and spleen removed from a 63-year-old man were investigated including a broad panel of immunohistochemical stainings. KIT codon 816 mutation analysis was carried out by melting point analysis of nested PCR products amplified from DNA of pooled microdissected mast cells. The histomorphological features of the initial bone marrow showed diffuse infiltration by hairy cell leukemia (HCL). Occult SM was only detected retrospectively by demonstration of a slight diffuse increase in loosely scattered, spindle-shaped mast cells carrying the activating point mutation KIT ( D816V ). In the second bone marrow, core biopsy removed about two years later HCL had been completely eradicated, while a diagnosis of SM-AHNMD with multifocal compact mast cell infiltrates associated with a myeloproliferative neoplasm (MPN) and significant increase in eosinophilic granulocytes was established. The third and last bone marrow biopsy specimen lacked the features of both MPN and HCL but showed progression into a secondary mast cell leukemia (MCL) with a focal sarcomatous component. To the best of the authors' knowledge, this is the first description of a case of SM-AHNMD with coexisting hematological neoplasms of lymphatic and myeloid origin initially presenting as occult disease and terminating as secondary MCL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22661384     DOI: 10.1007/s12032-012-0261-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  27 in total

1.  Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications.

Authors:  L Escribano; A Orfao; B Díaz-Agustin; J Villarrubia; C Cerveró; A López; M A Marcos; C Bellas; S Fernández-Cañadas; M Cuevas; A Sánchez; J L Velasco; J L Navarro; J F Miguel
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

Review 2.  Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria.

Authors:  Peter Valent; Cem Akin; Wolfgang R Sperr; Luis Escribano; Michel Arock; Hans-Peter Horny; John M Bennett; Dean D Metcalfe
Journal:  Leuk Res       Date:  2003-07       Impact factor: 3.156

Review 3.  Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.

Authors:  H P Horny; P Valent
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

4.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

5.  Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.

Authors:  Jorge Cortes; Patricia Ault; Charles Koller; Deborah Thomas; Alessandra Ferrajoli; William Wierda; Mary B Rios; Laurie Letvak; Elizabeth S Kaled; Hagop Kantarjian
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

6.  Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance.

Authors:  Alexandra Böhm; Manuela Födinger; Friedrich Wimazal; Oskar A Haas; Matthias Mayerhofer; Wolfgang R Sperr; Harald Esterbauer; Peter Valent
Journal:  J Allergy Clin Immunol       Date:  2007-04-23       Impact factor: 10.793

7.  A case of bone marrow mastocytosis associated with multiple myeloma.

Authors:  W Hagen; J Schwarzmeier; S Walchshofer; N Zojer; A Chott; C Sillaber; J Ackermann; I Simonitsch; H J Bühring; J Drach; K Lechner; H P Horny; P Valent
Journal:  Ann Hematol       Date:  1998 Mar-Apr       Impact factor: 3.673

Review 8.  Mastocytosis: state of the art.

Authors:  Hans-Peter Horny; Karl Sotlar; Peter Valent
Journal:  Pathobiology       Date:  2007       Impact factor: 4.342

9.  KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.

Authors:  Irina Maric; Jamie Robyn; Dean D Metcalfe; Michael P Fay; Melody Carter; Todd Wilson; Weiming Fu; Jennifer Stoddard; Linda Scott; Marilyn Hartsell; Arnold Kirshenbaum; Cem Akin; Thomas B Nutman; Pierre Noel; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2007-07-12       Impact factor: 10.793

10.  Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.

Authors:  H-P Horny; K Sotlar; W R Sperr; P Valent
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

View more
  3 in total

1.  Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis.

Authors:  H Hägglund; B Sander; A Ahmadi; T Gülen; G Nilsson
Journal:  Med Oncol       Date:  2014-07-18       Impact factor: 3.064

2.  Morphologic Confounders and CD19 Negativity in a Case of Hairy Cell Leukemia.

Authors:  Pulkit Rastogi; Sreejesh Sreedharanunni; Uday Yanamandra; Man Updesh Singh Sachdeva; Neelam Varma
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-05-01       Impact factor: 2.576

3.  Clinical Outcomes of Adults with Systemic Mastocytosis: A 15-Year Multidisciplinary Experience.

Authors:  Johanna Ungerstedt; Christopher Ljung; Monika Klimkowska; Theo Gülen
Journal:  Cancers (Basel)       Date:  2022-08-16       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.